Therma Bright Inc Stock Price, News & Analysis

Therma Bright (OTCQB:TBRIF) has expanded its strategic partnership with Gen-X Med for the distribution of Venowave™ VW5 devices. This follows an initial 200-unit sale announced in April 2025, targeting specialized knee surgeons in the U.S. healthcare network.

The partnership focuses on the growing specialized knee surgery market segment, with Gen-X Med reporting positive patient outcomes from the initial deployment. The global compression therapy market, valued at $4.18 billion in 2024, is projected to reach $6.72 billion by 2033, growing at a CAGR of 7.30%.

Therma Bright (OTCQB: TBRIF) has announced plans to amend the exercise price of 6,250,000 post-consolidation common share purchase warrants. The company proposes to reduce the exercise price from $0.80 to $0.06 per share for warrants issued during a Private Placement in June 2024.

Of the total warrants, 1,162,500 are held by company insiders, but due to TSXV policies, only 625,000 insider-held warrants will be eligible for repricing. The warrants maintain their original expiry dates of June 10 and June 20, 2027. Additionally, the company has received approval to postpone its 2025 annual general meeting to November 2025.

Therma Bright (OTCQB: TBRIF) has announced a significant 1:8 share consolidation effective July 8, 2025. The company's outstanding shares will be reduced from 454,457,147 to approximately 56,807,143 shares post-consolidation.

The consolidation will affect all outstanding incentive stock options and warrants, which will be adjusted proportionally. Shareholders will receive new share certificates or Direct Registration Advice after submitting their pre-consolidation certificates with a letter of transmittal to Olympia Trust Company.

Therma Bright Inc. (TBRIF) has announced plans for an 8:1 share consolidation, pending TSX Venture Exchange approval. The consolidation will reduce the company's outstanding shares from 451,632,147 to approximately 56,454,018 shares. This strategic move aims to provide increased flexibility for future financings and business transactions. The consolidation will also proportionally adjust outstanding options, warrants, and other rights to acquire common shares. The Board of Directors approved this action under the company's Articles of Incorporation, which allows for consolidations up to 10:1 without shareholder approval. Therma Bright confirms this is their only consolidation in the past 24 months, complying with TSXV Policy 5.8.

Therma Bright (TBRIF) announced plans to amend the exercise price of 42,725,000 outstanding warrants from its June 2024 private placement, subject to TSXV approval. The warrants' exercise price will be modified to $0.05 per share until December 31, 2025, and $0.10 thereafter, with expiration remaining June 10, 2027. Of the total warrants, 8,750,000 are held by insiders, but due to TSXV policies, only 4,272,500 insider-held warrants can be repriced. Additionally, the company plans to settle $124,000 in debt through the issuance of 6,200,000 common shares at $0.02 per share, pending TSXV approval.

Therma Bright Inc. (TBRIF) reports significant progress in its InStatin subsidiary, which focuses on developing inhaled statin therapies for respiratory conditions. The company announced the appointment of Professor Sir Peter Barnes, a globally recognized respiratory expert, as a strategic advisor. Key developments include: (1) Completion of a rodent pharmacokinetic study to determine lung exposure duration with selected statins, (2) Dr. Amir Zeki receiving an NIH grant for conducting statin efficacy studies in monkeys using an ozone sensitization model, and (3) Engagement of Mike Rafa for IP development. InStatin's strategic focus on mild to moderate asthma treatment suggests a potentially faster regulatory approval pathway compared to the COPD market.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) has secured a new customer with an initial purchase order for 200 units of its Venowave VW5 product. The order comes from a key distributor in the Durable Medical Equipment sector, with potential for significant follow-on orders following a successful market launch over the next two months.

The company also announced two debt settlements: issuance of 2,000,000 common shares at $0.05 per share to settle $100,000 debt, and a proposed settlement of $24,000 debt through 676,000 common shares at $0.0355 per share.

Venowave is a Medicare and Medicaid-eligible device that enhances vascular and lymphatic flow in lower limbs. This FDA-designated Durable Medical Equipment operates on a rechargeable 1.5V NiMH AA battery and is designed for multi-patient use.

Therma Bright (TBRIF) is evaluating its manufacturing strategy for Venowave products in response to recent US tariff changes on Chinese-manufactured goods. The company is conducting a comprehensive review of manufacturing options including: complete onshoring to North America (Canada, USA, or Mexico), maintaining Chinese production with tariff mitigation strategies, or implementing a hybrid approach combining both locations.

The decision-making process considers multiple factors beyond costs, including:

• Supply chain resilience
• Production lead times
• Quality control measures
• Intellectual property protection
• Logistics efficiency
• Market access and geopolitical stability

The company continues to work with national distributors to expand Venowave's market presence. The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is an FDA-designated Durable Medical Equipment device that enhances vascular and lymphatic flow in lower limbs.

Therma Bright Inc (TSXV: THRM) (OTCQB: TBRIF) has secured an exclusive U.S. marketing and distribution contract with Global Wellness Products , a subsidiary of Image Protect, Inc. (OTC Pink: IMTL), for its consumer product devices.

The partnership will initially focus on marketing the InterceptCS cold sore prevention device, followed by the rollout of other products including the Benepod hot-and-cold pain therapy device and TherOZap insect bite therapy device. This strategic move comes after Therma Bright's 2024 focus on promoting their Venowave product following permanent HCPCS code receipt.

The agreement targets the global cold sore treatment market, which was valued at USD$1.02 Billion in 2024 and is projected to reach USD$1.57 billion by 2031, according to Coherent Research.